EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sequential Plasma Metabolome and Proteome Analyses to Develop a Novel Monitoring Strategy for Patients with Epithelial Ovarian Cancer: A Pilot Study

Eiji Hishinuma, Shogo Shigeta, Naomi Matsukawa, Yasunobu Okamura iD, Ikuko N Motoike, Takamichi Minato, Yusuke Shibuya, Jun Yasuda iD, Kengo Kinoshita, Seizo Koshiba, Muneaki Shimada iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Eiji Hishinuma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8573, Japan. Hauptthemen laut MEDLINE: Metabolome, Carcinoma, Ovarian Epithelial, Proteome, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tohoku Medical Megabank Project (Tohoku University) of the MEXT and the Japan Agency for Medical Research and Development, Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED, Japan Society for the Promotion of Science (JSPS) KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial ovarian cancer (EOC) is diagnosed at an advanced stage in over half of the patients and its prognosis remains unfavorable. CA125, one of the most frequent positive tumor markers in patients with EOC, has certain limitations. Therefore, more accurate clinical biomarkers are needed. Liquid biopsy with cancer related molecules, such as circulating tumor DNA, is a new option for cancer diagnosis and prognosis. We explored the potential of plasma metabolomic and proteomic analyses as novel monitoring methods for the patients with EOC. Of seven patients, six experienced disease recurrence or progression. CA125 plasma measurements were conducted for disease monitoring. Plasma metabolome and proteome analyses were performed using liquid chromatography–tandem mass spectrometry. Ten and four metabolome indicators were significantly increased and decreased in association with chemotherapeutic resistance, respectively. In addition, thirty-seven and nine proteins displayed high and low levels associated with chemotherapeutic resistance, respectively. Several metabolome pathways and protein concentrations corresponded to the clinical course of each patient. This pilot study suggested the potential of the assessment of metabolome and proteome analysis as a useful tool for developing novel monitoring biomarkers for patients with recurrent EOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetabolomeCarcinoma, Ovarian EpithelialProteomeBiomarkers, TumorOvarian NeoplasmsHumansFemalePilot ProjectsMiddle AgedProteomicsAgedAdultCA-125 AntigenTandem Mass SpectrometryMetabolomicsPrognosisChromatography, LiquidNeoplasm Recurrence, Local

Stichwörter der Autor:innen

biomarkercirculating tumor DNAepithelial ovarian cancermetabolomicsproteomics

Substanzen

ProteomeBiomarkers, TumorCA-125 Antigen

Autor:innen und Institutionen

  • Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8573, Japan.
  • Tohoku Medical Megabank Organization, Tohoku University, Sendai 980-8573, Japan.
  • Department of Gynecology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan.
  • Systems Bioinformatics, Graduate School of Information Sciences, Tohoku University, Sendai 980-8579, Japan.
  • Department of Obstetrics and Gynecology, Hachinohe City Hospital, Hachinohe 031-8555, Japan.
  • Division of Molecular and Cellular Oncology, Miyagi Cancer Center, Natori 981-1293, Japan.

ORCID-Profile: Yasunobu Okamura, Jun Yasuda, Muneaki Shimada

Förderung

  • Tohoku Medical Megabank Project (Tohoku University) of the MEXT and the Japan Agency for Medical Research and Development
  • Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from AMED
  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • INGEM grant

Zitieren

APA

Hishinuma, E., Shigeta, S., Matsukawa, N., Okamura, Y., Motoike, I. N., Minato, T., Shibuya, Y., Yasuda, J., Kinoshita, K., Koshiba, S., & Shimada, M. (2025). Sequential Plasma Metabolome and Proteome Analyses to Develop a Novel Monitoring Strategy for Patients with Epithelial Ovarian Cancer: A Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125435

Vancouver

Hishinuma E, Shigeta S, Matsukawa N, Okamura Y, Motoike IN, Minato T, et al. Sequential Plasma Metabolome and Proteome Analyses to Develop a Novel Monitoring Strategy for Patients with Epithelial Ovarian Cancer: A Pilot Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125435

BibTeX
@article{Hishinuma2025,
  author = {Hishinuma, Eiji and Shigeta, Shogo and Matsukawa, Naomi and Okamura, Yasunobu and Motoike, Ikuko N and Minato, Takamichi and Shibuya, Yusuke and Yasuda, Jun and Kinoshita, Kengo and Koshiba, Seizo and Shimada, Muneaki},
  title = {Sequential Plasma Metabolome and Proteome Analyses to Develop a Novel Monitoring Strategy for Patients with Epithelial Ovarian Cancer: A Pilot Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125435}
}
Kostenlos starten →